DUBLIN – Funding continues to flow to European biotech, with Cardio3 Biosciences SA and Quantum Genomics SA raising €32 million (US$36 million) and €12.9 million (US$14.44 million), respectively, in secondary offerings last week. Both transactions confirm the current appetite among investors for European biotech, but a much sterner test of that support is on the near-term horizon, as a new Irish-American firm Malin Corp. plc unveiled ambitious plans to raise €275 million to €325 million in an IPO in Dublin shortly. Read More
Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco. Read More
In 2012, the Agency for Healthcare Research and Quality (AHRQ) set out to develop the Registry of Patient Registries (RoPR) as a one-stop repository of information about patient registries focused on, but not exclusive to, U.S.-based registries. The goals, in a nutshell, were to increase collaboration, reduce redundancy and improve transparency during drug and medical device development. Read More
Researchers gathered in Seattle last week to share their latest progress in fighting HIV and the infectious diseases that come in its wake at the 2015 annual Conference on Retroviruses and Opportunistic Infections. Read More
Rather than seeking a new partner after a worldwide licensing deal with Roche AG quietly terminated last year, privately held Chiasma Inc. decided to take its new drug application (NDA)-ready oral octreotide to market in the U.S. on its own. Read More
Boehringer Ingelheim (BI) GmbH's clinical hold on the oral beta secretase (BACE) inhibitor BI 1181181 for Alzheimer's disease (AD) because of skin reactions in some patients put a dent in shares of partner Vitae Pharmaceuticals Inc., but if worse comes to worse, the pair can move on to a different, structurally distinct candidate in the same class that's ready for testing. Read More
Bionomics Ltd., of Adelaide, Australia, said it plans to present additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando. Read More
Celldex Therapeutics Inc., of Hampton, N.J., said underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1.09 million shares of common stock at the public offering price of $24. Read More
Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said it recorded $51.7 million in net product sales of Juxtapid (lomitapide) capsules in the fourth quarter of 2014, representing growth of approximately 111 percent over the fourth quarter of 2013. Read More
Gilead Sciences Inc., of Foster City, Calif., reported detailed 48-week results from two phase III studies (Studies 104 and 111) testing its once-daily, single-tablet regimen containing tenofovir alafenamide (TAF) in HIV-1 infection in treatment-naïve adults. Read More
Mylan N.V., of Potters Bar, UK, and Mylan Inc., of Pittsburgh, completed the acquisition of Abbott's non-U.S. developed markets specialty and branded generics business. The transaction was valued at approximately $5.3 billion. Read More
A group at Yale University has developed a mitochondrial-targeted drug that was able to reverse type 2 diabetes and nonalcoholic steatohepatitis – fat in the liver in combination to a degree that has led to inflammation and liver damage – in obese mice. Read More
